Preventing and treating Alzheimer’s disease: strategies and prospects

References

• Katzman R. The prevalence and malignancy of Alzheimer's disease. Arch. Neurol. 33,217(1976).
   PubMed Web of Science ®Google Scholar
• Katzman R, Bick K. Alzheimer's Disease: the Changing View. New Yolk Academic Press, NY, USA (2000).
   Google Scholar
• Pollen DA. Hannah's Heirs: the Que s tFo r the Genetic Origins of Alzheimer's Disease. Oxford University Press, NY, USA (1993).
   Google Scholar
• Bernheimer H, Hornykiewicz, 0. Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism. Klin. Wochenschr . 43,711-715(1965).
   Google Scholar
• Drachman D, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch NeuroL 30,113–121 (1974).
   PubMed Web of Science ®Google Scholar
• Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99(3),459–496 (1976).
   PubMed Web of Science ®Google Scholar
• White P, Hiley CR, Goodhardt MJ et al. Neocortical cholinergic neurons in elderly people. Lancet 1(8013), 668–671 (1977).
   PubMed Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2(8000), 1403 (1976).
   PubMed Web of Science ®Google Scholar
• Davies P, Verth AH. Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res. 138(2), 385–392 (1977).
   Google Scholar
• Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10(2), 122–126 (1981).
   Google Scholar
• Summers WK, Viesselman JO, Marsh GM, Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. BioL Psych. 16(2), 145–153 (1981).
   Google Scholar
• Davis KL, Thal U, Gamzu ER et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N. Engl. J. Med. 327(18), 1253–1259 (1992).
   Google Scholar
• Francis PT, Palmer AM, Sims NR et aL Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. EngL J. Med. 313(1), 7–11 (1985).
   Google Scholar
• Glenner GG, Wong C W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Corn. 120(3), 885–890 (1984).
   Google Scholar
• Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 924, 17–25 (2000).
   Google Scholar
• Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594), 789–791 (2002).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. PharmacoL Toxicol. 43,545–584(2003).
   PubMed Web of Science ®Google Scholar
• Schenk D, Seubert P, Ciccarelli RB. Immunotherapy with I3-amyloid for Alzheimer's disease: a new frontier. DNA Cell. Biol. 20(11),679-681 (2001).
   Google Scholar
• Plant LD, Boyle J P, Smith IF, Peers C, Pearson HA. The production of amyloid 13 peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23(13), 5531–5535 (2003).
   Google Scholar
• Price DL, Whitehouse PJ, Struble RG et aL Alzheimer's disease and Down's syndrome. Ann. NY Acad. Sci. 396, 145–164 (1982).
   PubMedGoogle Scholar
• Wisniewski HM, Rabe A. Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann. NY Acad. Sci. 477, 247–260 (1986).
   PubMed Web of Science ®Google Scholar
• Goate A. Molecular genetics of Alzheimer's disease. Geriatrics 52\(Suppl. 2), S9—S12 (1997).
   Google Scholar
• St George-Hyslop P, Haines J et aL Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nature Ge n. 2(4), 330–334 (1992).
   Google Scholar
• Saunders A, Strittmatter W, Schmechel D et aL Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 4 3, 1467–1472 (1993).
   Google Scholar
• Mayeux R, Saunders A, Shea S etal. Utility of apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. EngL J. Med. 338, (1998).
   Google Scholar
• Duff K, Eckman C, Zehr C et aL Increased amyloid-13 42(43) in brains of mice expressing mutant presenilin 1. Na t u re383(6602), 710–713 (1996).
   Google Scholar
• Savonenko AV, Xu GM, Price DL, Borchelt DR, Markowska AL. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. NeurobioL Dis. 12(3), 194–211 (2003).
   PubMed Web of Science ®Google Scholar
• Refolo LM, Pappolla MA, LaFrancois J et al. A cholesterol-lowering drug reduces I3-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8(5), 890–899 (2001).
   Google Scholar
• Seshadri S, Drachman D, Lippa C. Apolipoprotein E e4 allele and the lifetime risk of Alzheimer's disease: what physicians know and what they should know. Arch. Ne u ro 1. 52, 107 4–1080 (1995).
   Google Scholar
• Drachman D. Aging and the brain: a new frontier. Ann. NeuroL 42, 819–828 (1997).
   PubMed Web of Science ®Google Scholar
• Beal M. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. NeuroL 38, 357–366 (1995).
   PubMed Web of Science ®Google Scholar
• Wei Y-H, Kao S-H, Lee H-C. Simultaneous increase of mitochondrial DNA detections and lipid peroxidation in human aging. In: Pharmacological Intervention in Aging and Age-Associated Disorders. Kitani K, Aoba A, Goto S (Eds). New York Academy of Sciences, NY, USA, 24–43 (1996).
   Google Scholar
• Buee L, Hof PR, Bouras C et aL Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathologica 87(5), 469–480 (1994).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Hunsaker JC 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11(6), 601–607 (1990).
   Google Scholar
• Strittmatter W, Saunders A, Schmechel D et al. Apolipoprotein E: high-avidity binding to I3-amyloid and increased frequency of Type 4 allele in late-onset familial Alzheimer's disease. Pr o c . Nail Acad. Sci. USA 90, 1977-1981 (1993).
   Google Scholar
• Jick H, Zornberg G, Jick S, Seshadri S, Drachman D. Statins and the risk of dementia. Lancet 356, 1627–1631 (2000).
   Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. NeuroL 57(10), 1439–1443 (2000).
   Google Scholar
• Rockwood K, Kirkland S, Hogan DB et aL Use of lipid-lowering agents, indication bias and the risk of dementia in community-dwelling elderly people. Arch. NeuroL 59(2), 223–227 (2002).
   PubMed Web of Science ®Google Scholar
• Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer's disease I3-amyloid peptides AP 42 and AI3 40 in vitro and in vivo. Proc. Nat! Acad. Sci. USA 98(10), 5856–5861 (2001).
   Google Scholar